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Abstract
Background: Sleep problems are common in adults with attention-deficit/hyperactivity disorder
(ADHD). This analysis aimed to evaluate the impact of lisdexamfetamine dimesylate (LDX) on sleep
quality in adults with ADHD.
Methods: This 4-week, phase 3, double-blind, forced-dose escalation study of adults aged 18 to
55 years with ADHD randomized participants to receive placebo (n = 62), or 30 (n = 119), 50 (n
= 117), or 70 (n = 122) mg/d LDX, taken once a day in the morning. The self-rated Pittsburgh Sleep
Quality Index (PSQI) was administered at baseline and at week 4 to assess sleep quality. The PSQI
global score assesses 7 sleep components (subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction)
each scored from 0 (no difficulty) to 3 (severe difficulty).
Results: The mean baseline PSQI global score was 5.8 for LDX and 6.3 for placebo (P = .19)
indicating poor overall sleep quality. At endpoint, least squares (LS) mean change from baseline was
-0.8 for LDX vs -0.5 for placebo (P = .33). The daytime functioning component showed significant
improvement in LS mean change at endpoint for LDX compared with placebo (LDX -0.4 vs placebo
0.0, P = .0001). LS mean changes for the other 6 PSQI components did not significantly differ from
placebo. Sleep-related treatment-emergent adverse events with an incidence ≥2% in the active
treatment and placebo groups, respectively, were insomnia (19.3% and 4.8%), initial insomnia (5.0%
and 3.2%), middle insomnia (3.6% and 0%), sleep disorder (0.6% and 3.2%), somnolence (0.3% and
3.2%), and fatigue (4.7% and 4.8%), and were generally mild or moderate in severity.
Conclusion: For most subjects, LDX was not associated with an overall worsening of sleep quality
and significantly improved daytime functioning in adults with ADHD.
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Background
Attention deficit/hyperactivity disorder (ADHD), charac-
terized by a pattern of inattention and/or hyperactivity, is
one of the most prevalent psychiatric disorders worldwide
[1]. Often diagnosed in childhood, ADHD is thought to
affect as many as 8% of children globally [2-4]. Symptoms
of ADHD persist into adolescence and adulthood for
approximately two-thirds of childhood cases [5,6]. The
prevalence of ADHD in adults in the United States is esti-
mated to be 4.4% [7].
Subjective reports of sleep problems are frequent among
both adult and pediatric patients with ADHD [8,9]. The
relationship between sleep and ADHD is complex and
appears to be bidirectional in that ADHD affects sleep pat-
terns while sleep patterns can impact ADHD symptoms
[10]. The mechanisms by which ADHD can disturb sleep
have not been fully elucidated but may involve changes in
noradrenergic and/or dopaminergic systems. Further-
more, anatomical and functional regions of the central
nervous system responsible for ADHD symptoms and
those involved in sleep regulation seemingly overlap [10].
Patient reports of disturbed sleep are also significantly
associated with their current ADHD symptom severity. A
study by Kass et al demonstrated that daytime sleepiness
and insomnia were predictors of increased ADHD symp-
tomatology as assessed by the Adult Behavior Checklist in
young adults [11].
Sleep disturbances in ADHD may be a manifestation of
ADHD, itself, but may also result from medications used
to treat ADHD [10,12]. Sleep disturbances may also be
secondary to comorbid conditions [10,12]. It is possible
that sleep disturbances secondary to ADHD and/or phar-
macotherapy may also be contributing factors in driving-
related problems known to be associated with ADHD
[13].
The increased prevalence of sleep disturbances in adults
with ADHD may also be secondary to other behaviors or
conditions associated with ADHD. For instance, cigarette
use, which is significantly more common in adolescents
and adults with ADHD than in healthy controls, has been
shown to independently result in sleep disturbances,
including, but not limited to, less total sleep time,
extended sleep onset latency, and dissatisfaction with
sleep quality [5,14,15]. Caffeine intake is well known to
adversely affect sleep [16], but at the same time, may be
used to some extent for self-medication in adults with
ADHD [17]. There also appears to be an association
between obesity and ADHD [18]. Obesity is an important
risk factor for obstructive sleep apnea-hypopnea syn-
drome, a disorder associated with sleep fragmentation
and frequent nocturnal arousals leading to daytime sleep-
iness [19].
Although subjective reports of sleep disturbances in adults
with ADHD are frequent in the clinical literature, to date,
there is scant direct evidence of the occurrence of specific
sleep disorders in adults with ADHD [20]. Wagner et al
noted that ADHD symptoms were more common (26%)
in a cohort of subjects with restless leg syndrome (RLS)
than those with primary insomnia (6%) or normal con-
trols (5%) suggesting a link between ADHD and RLS in
adults [21]. A recent small (N = 6) pilot study found poly-
somnographic evidence of sleep-disordered breathing to
support subjective reports of sleep disturbances in adult
subjects with carefully diagnosed ADHD [22]. Another
case study further supports the notion that ADHD and
sleep-disordered breathing in the form of obstructive
sleep apnea may be associated [23]. A number of studies
have investigated the sleep patterns of subjects with
ADHD compared with healthy adults. Schredl et al dem-
onstrated that adults with ADHD rated their sleep quality
and feeling of being refreshed in the morning much lower
than healthy controls; sleep latency and nocturnal awak-
enings were marginally significantly different from con-
trols [24]. The cross-sectional study did not demonstrate
any effect of medication on sleep parameters as assessed
by patient-completed questionnaires. Using a combina-
tion of sleep log and actigraph results, Kooij and col-
leagues reported that adults with ADHD demonstrated
significantly poorer sleep quality and higher nocturnal
motor activity than their matched controls but did not dif-
fer in reported total time in bed, sleep latency, or number
of awakenings [25].
Along with Surman et al above [22], other studies have
provided further objective (eg, polysomnography or sleep
actigraphy) data regarding the relationship between
ADHD and sleep disturbances. Another study comparing
adults with ADHD to healthy control subjects demon-
strated significantly increased nocturnal motor activity
and more frequent arousals in the patients with ADHD
but did not find differences in other polysomnography
parameters, despite these patients with ADHD reporting
subjectively worse sleep quality than controls [26]. A
recent study by Sobanski et al demonstrated reduced sleep
efficiency, longer sleep onset latency, more frequent noc-
turnal awakenings, and altered sleep architecture in adults
with ADHD compared with controls [27].
In children with ADHD, subjective parental and patient
reports of sleep disturbances are common [28]. Recent
reports have linked ADHD in children to RLS, periodic
limb movement disorder (PLMD), and sleep-disordered
breathing [29-32]. Notably, however, objective sleep data
have not demonstrated uniform results regarding sleep
continuity or sleep architecture abnormalities in children
with ADHD [33]. Moreover, there have been relatively few
studies examining the effects of ADHD medications onBehavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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sleep parameters in children with ADHD, and most eval-
uate the effects of short-acting stimulants [33].
Stimulants are the mainstay of pharmacologic therapy for
adults with ADHD [2,4,34]. Approximately 7 million
Americans filled at least one prescription for an ADHD
therapy in 2007 [35]. Their effectiveness in reducing the
symptoms of ADHD in adults is well documented [36-
38]. Despite the lack of objective documentation of sleep
difficulties, clinical studies commonly report sleep diffi-
culties, namely delay of sleep onset and insomnia
[12,28,34,39]. As stimulants wear off, they are sometimes
associated with a rebound effect and a return of ADHD
symptoms. Depending on the timing of the last dose of
medication and the duration of effect for the drug, this
can coincide with bedtime and may result in a delay of
sleep onset [10,34,40]. However, the effects of stimulants
on sleep patterns in patients with ADHD have not been
fully elucidated [41], and it is clear that stimulants can
cause insomnia and result in sleep disturbances in some
patients [12,28,34,39].
There is some evidence that stimulants may improve sleep
in patients with ADHD. In one study, after 3 weeks of
treatment with stimulants, adults with ADHD demon-
strated reduced nocturnal motor activity and improved
sleep quality [25]. In another study, treatment with meth-
ylphenidate (MPH) resulted in significant reduction in
sleep onset latency and improved sleep efficiency, but did
not alter other parameters as measured by polysomnogra-
phy [27]. Studies of sleep actigraphy measuring gross
body movements over extended periods of time in adults
with ADHD demonstrated that although adults treated
with MPH experienced prolonged sleep onset latency and
decreased total sleep time, they also experienced a
decrease in nocturnal awakenings leading to more consol-
idated sleep reported as improved quality [42]. A recent
study by Faraone et al suggests that neither once-daily
OROS MPH nor transdermal MPH reliably caused sleep
problems (or worsened existing sleep problems) in chil-
dren with ADHD [43]. In another pediatric study, MPH
significantly prolonged sleep-onset latency while atomox-
etine decreased it [44]. In the same study, however, treat-
ment with atomoxetine was associated with significantly
more sleep interruptions than MPH [44]. So while it may
be apparent that stimulants can cause sleep disturbances
in some patients, the evidence is inconsistent.
Lisdexamfetamine dimesylate (LDX) is approved for the
treatment of ADHD in children aged 6 to 12 years and in
adults, and is the first prodrug stimulant. LDX is a thera-
peutically inactive molecule. After oral ingestion, LDX is
converted to l-lysine and active d-amphetamine, which is
responsible for the therapeutic effect. While a small
amount of LDX is hydrolyzed to d-amphetamine in the
gastrointestinal (GI) tract, the conversion of LDX into
active d-amphetamine occurs primarily in the blood. The
combination of l-lysine and d-amphetamine created a
new chemical entity with a prodrug technology of delivery
of d-amphetamine [45]. The absorption of LDX and its
conversion to d-amphetamine are not affected by the pH
of the GI system and is unlikely to be influenced by nor-
mal variations in GI transit times [46].
LDX has demonstrated efficacy in treating children and
adults with ADHD in multiple randomized, double-
blind, clinical trials. LDX has demonstrated significant
efficacy over placebo in improving ADHD rating scale Ver-
sion IV (ADHD-RS-IV-IV) scores, Swanson, Kotkin, Agler,
M-Flynn, and Pelham (SKAMP) rating scale scores, and
Permanent Product Measure of Performance (PERMP)
scores compared with placebo in children with ADHD
[47,48]. LDX was effective for up to 13 hours in a phase 3,
randomized, controlled trial in children in a laboratory
classroom study [49]. Adverse events (AEs) were consist-
ent with other pediatric studies of LDX.
In a large, randomized, controlled trial in adults with
ADHD, treatment with LDX resulted in significant
improvements in ADHD-RS-IV and Clinical Global
Impression (CGI) scores compared with placebo [50].
LDX was generally well tolerated in this study, and sub-
jects reported common nonsleep-related adverse events
including dry mouth and decreased appetite as well as
insomnia. The results of this study were previously pub-
lished. The present analysis, using the data-set from this
previously published study [50], evaluated the effects of
LDX on sleep parameters in adults with ADHD utilizing
the Pittsburgh Sleep Quality Index (PSQI), a validated
scale designed to measure overall sleep quality and related
aspects of sleep [51]. This analysis was undertaken to
describe the effects of LDX on sleep using the PSQI. Previ-
ously, the PSQI scale has not been extensively studied in
adult patients with ADHD.
Methods
This 4-week, double-blind, placebo-controlled, rand-
omized, parallel-group, forced-dose, escalation study of
LDX (Vyvanse®, Shire US Inc.) was conducted between
May and November 2006. Institutional Review Board
approval was obtained for each of the 48 study sites, and
all participants gave written informed consent after receiv-
ing a full explanation of the study.
Inclusion/Exclusion Criteria
Adults aged 18 to 55 years with a primary diagnosis of
ADHD by Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition, Text Revision (DSM-IV-TR) criteria
were eligible for study enrollment. Investigators estab-
lished a diagnosis of ADHD based on a psychiatric evalu-Behavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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ation utilizing the Adult ADHD Clinical Diagnostic Scale.
Participants were required to have clinician-rated ADHD-
RS-IV scores of at least 28 at baseline using adult prompts
developed by New York University and Massachusetts
General Hospital [52,53]. This score indicates moderate
to severe ADHD symptoms. Patients were excluded from
the study if they had any comorbid psychiatric diagnosis
with significant symptoms, hypertension, significant
abnormality on electrocardiogram (ECG), history of sei-
zures (other than infantile febrile seizures), or were signif-
icantly underweight or morbidly obese. Insomnia or
sleep-related conditions were not listed as exclusion crite-
ria. Additionally, subjects taking any medications that
affect the central nervous system or blood pressure
(excluding ADHD medications that were discontinued
during a washout period) or those with a current or recent
history of drug dependence or substance abuse (excluding
nicotine) were also excluded from the study. Specifically,
prohibited therapies relevant to this sleep analysis
included sedatives, sedative-hypnotics such as zopiclone,
sedating antihistamines (as a single preparation or in
combination), anxiolytics, benzodiazepines, and benzo-
diazepine derivatives.
Study Design and Measures
The present study had 3 phases: 1) screening and wash-
out; 2) baseline; and 3) double-blind treatment. After a
screening period to determine eligibility, subjects were
asked to discontinue all ADHD medications for at least 7
days (28 days if the patient was taking atomoxetine). At
the baseline visit, enrolled participants completed base-
line assessments and were randomized to receive placebo
or once-daily oral doses of LDX of 30 mg, 50 mg, or 70 mg
during the 4-week, double-blind period. All subjects ran-
domized to receive LDX began treatment with 30 mg
doses. Subjects randomized to receive 50 mg/d LDX
underwent a 1-week, forced-dose escalation schedule,
while those randomized to the 70 mg/d LDX group
underwent a 2-week escalation. During the 4-week, dou-
ble-blind period, subjects attended weekly clinic visits for
evaluation and drug distribution and were contacted
within 30 days following their last dose of study medica-
tion to collect information about serious AEs. ADHD-RS-
IV total score at endpoint was the primary efficacy meas-
ure in the present study.
Safety assessments included the recording of AEs, vital
signs, ECGs, clinical laboratory tests, and physical exami-
nations. AEs were collected at every study visit after screen-
ing and were coded using the Medical Dictionary for
Regulatory Activities (MedDRA version 9.1. Reston, VA).
Sleep quality was assessed using the PSQI administered at
baseline and at the endpoint (ie, week 4 or early termina-
tion). The PSQI consists of 19 self-rated questions and 5
questions intended to be completed by the subject's
roommate or bed partner (if applicable) [51]. The 19 self-
rated questions are grouped into 7 component scores:
subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleep-
ing medications, and daytime dysfunction. Each compo-
nent score ranges from 0 (no difficulty) to 3 (severe
difficulty) and contributes equally to a PSQI global score
that ranges from 0 to 21. Negative change scores indicate
improvement on the PSQI. This validated instrument has
been shown to be a sensitive and specific measure of sleep
quality over a 1-month interval [51]. The PSQI underwent
field testing, which demonstrated that the questionnaire
is considered easy to use by subjects and patients. In addi-
tion, field testing showed that the 7 major components, as
well as the 19 individual questions, are internally consist-
ent. Responses for global scores, component scores, and
individual question responses are stable across time, and
its validity is supported by its ability to discriminate
patients from controls [51]. Higher PSQI scores represent
poorer sleep quality with global scores >5 generally con-
sidered to indicate poor sleep quality (diagnostic sensitiv-
ity of 89.6% and specificity of 86.5%) [51]. Furthermore,
global scores >5 indicate that the subject is having severe
difficulties in at least 2 areas, or moderate difficulties in
more than 3 areas. The global score, thus, conveys infor-
mation about the severity of the subject's sleep problems
and the number of potential problems present [51].
Data Analysis
The intent-to-treat (ITT) population, defined as all sub-
jects randomized to treatment and who had both a base-
line and at least 1 post-randomization ADHD-RS-IV total
score available, was the primary population for efficacy
analyses while safety analyses were performed on the
safety population, defined as all subjects who received the
study drug.
The primary efficacy analysis was performed on the
change from baseline in ADHD-RS-IV total score at treat-
ment endpoint, using a two-way analysis of covariance
(ANCOVA). This method yielded results numerically
identical to the last observation carried forward (LOCF)
approach. To compare the ADHD-RS-IV change from
baseline of the 3 LDX treatment groups with those
patients receiving placebo, Dunnett's test for multiple
mean comparisons with least-squares (LS) adjustment
was used.
For safety analyses, the length of exposure to the study
drug was categorized by week (ie, 1 week = 1 to 7 days, 2
weeks = 8 to 14 days, etc) and was determined by the dates
of first dispensing and last dose of the study drug. AEs
were reported as either prerandomization AEs or treat-
ment-emergent AEs (TEAEs) based on the starting date ofBehavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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the AE in relation to the date randomized treatment was
initiated. Events with missing start dates were considered
TEAEs that began on the first date of treatment.
PSQI global and component scores were summarized by
treatment for baseline and at endpoint (the final study
visit) using the number of observations, mean, and stand-
ard deviation (SD). Changes in PSQI global and compo-
nent scores from baseline were analyzed for differences at
endpoint among treatment groups using the ANCOVA
model. Dunnett's test for multiple mean comparisons
with LS adjustment was utilized to compare the change
from baseline of the 3 active treatment groups with the
placebo group. Post hoc analyses included analyses of 2
questions in the PSQI requiring subjects to report time
measures (sleep onset latency and sleep duration).
Results
Subject Demographics and Disposition
The disposition of the 420 enrolled subjects is shown in
Figure 1. The safety population was composed of the 420
participants and the ITT population consisted of 414 sub-
jects (n = 115, 117, 120, and 62 for the 30 mg/d, 50 mg/
d, 70 mg/d, and placebo groups, respectively). Of the
enrolled subjects, 71 (17%) discontinued prior to study
completion while 349 (83%) completed the study (Figure
1). For purposes of the PSQI, the safety population
included only those patients at endpoint with a valid end-
point PSQI measurement (n = 402). Most subjects report-
ing sleep-related AEs while receiving LDX (103 of 109
subjects) or placebo (8 of 9 subjects) and all subjects (n =
9) discontinuing the study due to sleep-related AEs had
both baseline and endpoint PSQI scores and were
included in the analysis of sleep quality.
The treatment groups were well matched at baseline.
Slightly more men than women were included in the
safety population (between 51.6% and 56.4% were men
across the groups). The mean age (SD) of the placebo
group was 35.2 (10.9) years while the mean age in the
LDX groups ranged from 34.2 (10.0) years to 35.8 (10.5)
years. The mean (SD) weight of the placebo group was
181.3 (39.1) lb and the LDX groups ranged from 173.1
(37.8) lb to 178.1 (38.9) lb. The majority of subjects were
Caucasian, making up 77.4% of the placebo group and
79.0% to 88.5% of the LDX groups. Disease severity, as
assessed by ADHD-RS-IV total score and CGI-Severity, was
similar among groups at baseline. Global PSQI scores at
baseline were similar for all groups and indicated overall
poor sleep quality with mean (SD) scores of 6.3 (3.20),
5.4 (2.53), 5.9 (3.01), and 6.0 (2.76) for the placebo, 30
mg/d LDX, 50 mg/d LDX, and 70 mg/d LDX groups,
respectively. At baseline, 46.7%, 44.4%, 45.5%, and
57.3% of subjects in the placebo, 30 mg/d LDX, 50 mg/d
LDX, and 70 mg/d LDX groups, respectively, rated their
sleep as overall poor quality by global PSQI scores.
Efficacy and Tolerability Findings from the Parent Study
Subjects receiving LDX showed significant improvement
vs placebo in ADHD symptoms, measured by ADHD-RS-
IV scores, and significant improvement in symptom sever-
ity vs placebo, measured by the Clinical Global Impres-
sions-Improvement scale. AEs included dry mouth,
decreased appetite, and insomnia; and were generally
mild [50].
Changes in PSQI Scores
At endpoint, the mean global PSQI score, a composite of
all component scores, for all treatment groups decreased
from baseline (Figure 2). The global PSQI score LS mean
(SE) change from baseline of the placebo group was -0.5
(0.26) and the combined LDX groups demonstrated LS
mean (SE) changes of -0.8 (0.11) (P = .33). LDX treatment
was not associated with a significant change from baseline
Subject disposition Figure 1
Subject disposition. (LDX = lisdexamfetamine dimesylate; AEs = adverse events).
Randomized
Completed
Discontinued
30 mg/d LDX
n=119
(28%)
n=16
(13%)
4 for AEs
1 for lack of efficacy
3 for protocol violation
n=103
(87%)
Placebo
n=62
(15%)
n=10
(16%)
1 for AEs
4 for lack of efficacy
2 for protocol violation
n=52
(84%)
70 mg/d LDX
n=122
(29%)
n=24
(20%)
9 for AEs
1 for lack of efficacy
7 for protocol violation
n=98
(80%)
50 mg/d LDX
n=117
(28%)
n=21
(18%)
8 for AEs
2 for lack of efficacy
7 for protocol violation
n=96
(82%)Behavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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compared with placebo indicating that there was no wors-
ening of or impact on sleep quality with LDX. Further
analyses employing Dunnett's test for multiple mean
comparisons demonstrated that there were no significant
differences in mean change from baseline at endpoint for
any LDX dose group compared with placebo.
The mean changes from baseline at endpoint for the com-
ponents of the PSQI, subjective sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep
disturbances, and use of sleep medication, were not signif-
icantly different between patients treated with any LDX
dose and those receiving placebo.
The PSQI requires subjects to report average sleep onset
(in minutes) and sleep duration (in hours) over the
course of the month preceding the assessment. At base-
line, the mean (SD) sleep onset latency for the placebo
group was 30.2 (28.34) minutes compared with 24.8
(24.03) minutes for the combined LDX treatment group.
Compared with placebo, LDX was not associated with sig-
nificant prolongation of sleep onset (Table 1). In addi-
tion, LDX was not associated with significant changes in
sleep duration from baseline at endpoint compared with
placebo. LDX treatment was associated with change from
baseline in sleep duration with LS mean (SE) of -0.2
Effect of LDX on global PSQI scores Figure 2
Effect of LDX on global PSQI scores. Mean global PSQI scores of all treatment groups decreased from baseline indicating 
an improvement in sleep quality. Numbers within bars indicate numbers of subjects. (SD = standard deviation; SE = standard 
error; LS = least squares; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate).
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Baseline (±SD) Endpoint (±SD) Change (LS Mean ±SE)
Placebo
62 61
30 mg/d LDX
119 111
50 mg/d LDX
116 113
70 mg/d LDX
121 117
All LDX Doses
356 341
Table 1: Effect of LDX on Sleep Onset (in minutes) as Assessed by the PSQI
Placebo
(n = 62)
30 mg/d LDX
(n = 119)
50 mg/d LDX
(n = 116)
70 mg/d LDX
(n = 121)
All LDX Doses
(n = 356)
Baseline
[Mean (SD)]
30.2
(28.34)
22.6
(20.84)
26.6
(26.44)
25.1
(24.56)
24.8
(24.03)
Endpoint
[Mean (SD)]
28.1
(32.64)
20.1
(18.23)
27.9
(26.73)
29.3
(31.19)
25.9
(26.27)
Change
[LS Mean (SE)]
-1.2
(2.78)
-3.5
(2.09)
0.4
(2.06)
4.0
(2.04)
0.4
(1.23)
Sleep onset reported in minutes.
SD = standard deviation; SE = standard error; LS = least squares; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate.Behavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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(0.07) hour compared with -0.1 (0.15) for placebo (Table
2).
Analysis of change from baseline in PSQI component
scores demonstrated significant differences between treat-
ment with LDX and placebo on the daytime dysfunction
(trouble staying awake or lack of enthusiasm) component
(ie, component 7) as shown in Figure 3. At endpoint, the
LS mean (SE) changes from baseline of the PSQI daytime
dysfunction score was 0.0 (0.08) for the placebo group
and -0.4 (0.04) for the LDX all dose group (P = .0001).
Significant improvements from baseline were evident for
all individual LDX dose groups compared with placebo (P
≤ .01 for each). The placebo-adjusted LS mean changes
from baseline for the 30 mg/d, 50 mg/d, and 70 mg/d
LDX groups were -0.3, -0.3, and -0.4, respectively.
Concomitant Medications and Sleep-related Treatment-
emergent Adverse Events
As previously mentioned, the use of sleep-inducing medi-
cations was prohibited in the protocol of this study. How-
ever, over the course of the trial, the use of sleep
medications appeared evenly distributed across the dos-
age groups. Diphenhydramine and diphenhydramine
hydrochloride were used by 10 subjects (placebo: 2; 30
mg/d LDX: 6; 50 mg/d LDX: 1; 70 mg/d LDX: 1). Some
instances of diphenhydramine use were related to treat-
ment of allergic reactions/poison ivy or to respiratory
symptoms and not for treatment of sleep disorders. Zolpi-
dem tartrate and melatonin were each used by 1 subject
during the study (30 mg/d LDX and placebo group,
respectively).
The incidences of all sleep-related TEAEs are listed in
Table 3. The TEAEs with an incidence of at least 2% in any
treatment group were initial insomnia (3.2%, 3.4%,
6.0%, and 5.7% for placebo, 30 mg/d, 50 mg/d, and 70
mg/d, respectively), insomnia (4.8%, 19.3%, 17.1%, and
21.3%, respectively), middle insomnia (0%, 4.2%, 1.7%,
and 4.9%, respectively), somnolence (3.2%, 0.8%, 0%,
and 0%, respectively), fatigue (4.8%, 7.6%, 4.3%, and
2.5%, respectively), and sleep disorder (3.2%, 0%, 1.7%,
and 0%, respectively). Insomnia was reported as a TEAE
by 14% (n = 50) of patients taking LDX during week 1,
2.6% (n = 9) in week 2, 3.1% (n = 10) in week 3, and 2.3%
(n = 7) in week 4 and beyond. For patients receiving pla-
cebo, insomnia was reported by 3.2% (n = 2) during week
1, by 1.7% (n = 1) during week 2, and was not reported in
later weeks. Sleep-related TEAEs in patients receiving LDX
were generally mild or moderate in severity (Table 4). The
only sleep-related TEAEs to be recorded as severe were
insomnia in 2.2% of subjects receiving LDX (n = 8),
fatigue in 0.6% of subjects in the LDX groups (n = 2) and
nightmares in 0.3% of subjects in the LDX groups (n = 1).
Treatment with LDX was not associated with any deaths or
serious AEs in this study.
To investigate whether a relationship exists between the
reported incidence of sleep-related TEAEs and subjective
reports of sleep quality, we examined changes in PSQI
scores of subjects reporting various sleep-related TEAEs.
For subjects in all LDX treatment groups combined (n =
109) and in the placebo group (n = 9) who reported sleep-
related TEAEs during the study, PSQI global scores from
baseline to endpoint did not appear to appreciably
worsen (Figure 4). For those subjects reporting TEAEs
unrelated to sleep (n = 181 for all LDX treatment groups
and n = 29 for placebo), there was a slight decline in PSQI
scores from baseline to endpoint.
Nine subjects (3 in the 30 mg/d LDX group, 3 in the 50
mg/d LDX group, and 3 in the 70 mg/d LDX group) with-
drew from the study due to sleep-related TEAEs. These 9
subjects reported a total of 10 sleep-related TEAEs (Table
5). Insomnia and other sleep-related TEAEs resulting in
discontinuation were rated as mild to moderate for 7 of
10 TEAEs and as severe insomnia for the remaining 3
TEAEs. All but one case of insomnia were reported as
resolved on follow-up. Discontinuations due to insomnia
and sleep disorder did not demonstrate a discernible pat-
tern with increasing LDX dose.
Table 2: Effect of LDX on Sleep Duration (in Hours) as assessed by the PSQI
Placebo
(n = 62)
30 mg/d LDX
(n = 119)
50 mg/d LDX
(n = 116)
70 mg/d LDX
(n = 121)
All LDX Doses
(n = 356)
Baseline
[Mean (SD)]
6.9
(1.34)
7.4
(1.69)
7.4
(1.51)
7.2
(1.42)
7.3
(1.54)
Endpoint
[Mean (SD)]
7.0
(1.33)
7.2
(1.21)
7.0
(1.44)
7.0
(1.61)
7.1
(1.43)
Change
[LS Mean (SE)]
-0.1
(0.15)
-0.1
(0.11)
-0.3
(0.11)
-0.2
(0.11)
-0.2
(0.07)
SD = standard deviation; SE = standard error; LS = least squares; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate.Behavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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Discussion
The present analyses compared the effects of LDX and pla-
cebo on sleep characteristics in adults with ADHD. The
data presented in this manuscript were collected as part of
a phase 3 trial in which LDX demonstrated significant effi-
cacy at reducing the symptoms of ADHD in adults com-
pared with placebo. To assess sleep parameters, subjects
were asked to complete the PSQI, a validated measure of
sleep quality, before treatment and again at the end of a 4-
week, double-blind treatment period or early termina-
tion, during which they were treated with placebo or any
of 3 LDX dosages. Additional sleep characteristics were
assessed by the analysis of sleep-related TEAEs.
Mean baseline global PSQI scores for all treatment groups
were greater than 5, confirming the results of previous
studies demonstrating that adults with ADHD report poor
sleep quality [8]. LDX was not associated with an overall
worsening of self-reported sleep quality. There was also
no difference or worsening between the LDX and placebo
groups with reference to the PSQI components of sleep
latency, sleep duration, sleep disturbances, sleep medica-
tions used, and habitual sleep efficiency. Furthermore,
LDX was not associated with significant alterations in
sleep duration or sleep onset latency compared with pla-
cebo. PSQI global scores decreased in all groups in the
direction of improvement, and these differences were not
statistically significant for LDX or placebo groups.
Analysis of individual PSQI components showed that
LDX significantly improved daytime functioning com-
pared with placebo. The PSQI assesses daytime function-
ing by asking subjects to report 1) how often they have
trouble staying awake during activity and 2) how much of
a problem they have keeping up enough enthusiasm to
get things done [51]. While the PSQI daytime functioning
component scores were statistically improved vs placebo
and the overall group change from baseline for the LDX
group on this component was ~30% (baseline mean of
1.25, endpoint mean of 0.87), the clinical significance of
this finding was difficult to assess since global PSQI scores
and other component scores were not significantly
improved. The PSQI component that assesses subject's
self-rating of sleep quality showed that, regardless of treat-
ment group, subjects rated their sleep quality at endpoint
as "fairly good" (mean scores of 1.03 and 0.97 for placebo
and combined all-active LDX treatment groups, respec-
tively).
Previous research has demonstrated a significant correla-
tion between the severity of ADHD symptoms and param-
eters of sleep quality. Schredl et al, using 2 sleep
Effect of LDX on daytime dysfunction (component 7) PSQI scores Figure 3
Effect of LDX on daytime dysfunction (component 7) PSQI scores. Mean PSQI component 7 score (daytime dysfunc-
tion component) decreased significantly after treatment with LDX. Numbers within bars indicate numbers of subjects. (SD = 
standard deviation; SE = standard error; LS = least squares; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine 
dimesylate). P-values for "all LDX doses" calculated by analysis of covariance with baseline score as covariate. P-values for indi-
vidual LDX dose groups calculated by Dunnett's test for multiple mean comparisons with least-squares (LS) adjustment. * P < 
.01 vs placebo.
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questionnaires (Schlaffragebogon B [SF-B] and Landexker
Inventar zur Erfassung con Schlafstörungen [LISST]),
demonstrated that ADHD symptoms were inversely and
closely related to the feeling of being refreshed in the
morning, and directly related to problems with sleep/
wake pattern, sleep quality, sleep latency, and tiredness
during the day [24]. The positive effect of LDX on a sub-
jective measure of daytime function and other data sug-
gestive of potentially broader positive effects on subjective
sleep measures in the present study are intriguing. In line
with this, other preliminary reports have described posi-
tive effects of stimulants on sleep quality in adults with
ADHD. In an open-label study of 8 adults with ADHD,
Kooij et al demonstrated that stimulants improved self-
reported sleep quality [25]. Recently, in a small, open-
label study, Sobanski et al found that stimulant therapy
was associated with significant improvements in the
restorative value of sleep as assessed by Schlaffragebogon
A (SF-A) [27]. Taken together, these findings indicate that
more studies that rigorously assess sleep quality with and
without treatment in adults with ADHD are needed.
Insomnia, middle insomnia, and initial insomnia were
reported as AEs more commonly in patients receiving LDX
than those patients receiving placebo. This reported inci-
dence of insomnia markedly decreased after week 1,
which cannot be accounted for by study discontinuations.
Table 3: Sleep-Related TEAEs
n (%) Placebo
(n = 62)
30 mg/d LDX
(n = 119)
50 mg/d LDX
(n = 117)
70 mg/d LDX
(n = 122)
Active Doses
(n = 358)
Initial insomnia 2 (3.2) 4 (3.4) 7 (6.0) 7 (5.7) 18 (5.0)
Insomnia 3 (4.8) 23 (19.3) 20 (17.1) 26 (21.3) 69 (19.3)
Middle insomnia 0 (0) 5 (4.2) 2 (1.7) 6 (4.9) 13 (3.6)
Somnolence 2 (3.2) 1 (0.8) 0 (0) 0 (0) 1 (0.3)
Sleep disorder 2 (3.2) 0 (0) 2 (1.7) 0 (0) 2 (0.6)
Abnormal dreams 0 (0) 0 (0) 0 (0) 1 (0.8) 1 (0.3)
Early morning awakening 0 (0) 0 (0) 0 (0) 1 (0.8) 1 (0.3)
Nightmare 0 (0) 0 (0) 0 (0) 2 (1.6) 2 (0.6)
Poor quality sleep 0 (0) 1 (0.8) 0 (0) 0 (0) 1 (0.3)
Hypersomnia 0 (0) 1 (0.8) 0 (0) 0 (0) 1 (0.3)
Fatigue 3 (4.8) 9 (7.6) 5 (4.3) 3 (2.5) 17 (4.7)
TEAEs = treatment-emergent adverse events; LDX= lisdexamfetamine dimesylate.
Table 4: Sleep-Related TEAEs on LDX by Severity
Active doses (n = 358) n (%) Mild Moderate Severe
Initial insomnia 11 (3.1) 7 (2.0) 0 (0)
Insomnia 37 (10.3) 28 (7.8) 8 (2.2)
Middle insomnia 7 (2.0) 7 (2.0) 0 (0)
Somnolence 1 (0.3) 0 (0) 0 (0)
Sleep disorder 1 (0.3) 1 (0.3) 0 (0)
Abnormal dreams 1 (0.3) 0 (0) 0 (0)
Early morning awakening 1 (0.3) 0 (0) 0 (0)
Nightmare 1 (0.3) 0 (0) 1 (0.3)
Poor quality sleep 0 (0) 1 (0.3) 0 (0)
Hypersomnia 0 (0) 1 (0.3) 0 (0)
Fatigue 9 (2.5) 6 (1.7) 2 (0.6)Behavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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Furthermore, most sleep-related TEAEs were mild or mod-
erate in severity and rarely resulted in subjects being dis-
continued from the trial. Interestingly, despite reports of
sleep-related TEAEs, global PSQI scores did not appear to
worsen in those subjects at the end of treatment. This
raises the possibility that frequency counts of AEs may not
be a strong predictor of qualitative, subject-reported clin-
ical consequences in this setting. The overall incidence of
sleep-related TEAEs in the present study compares favora-
bly with data for other medications used to treat ADHD in
adults. In 1 study, insomnia was reported by 37% of adult
patients receiving mixed amphetamine salts during a 7-
week trial and studies of atomoxetine, a nonstimulant,
reported insomnia as a TEAE in 20.8% of adult subjects
during 2 10-week trials [37,54].
Interestingly, despite insomnia being reported as a fre-
quent TEAE in patients receiving LDX, PSQI results indi-
cated that LDX was not associated with a worsening in
sleep duration, sleep onset latency, or sleep quality com-
pared with patients taking placebo. This suggests that
although insomnia was reported as an AE in this trial, sub-
jects did not feel it interfered with their overall sleep qual-
ity. A notion that is also supported by the finding that for
those subjects who reported insomnia as an AE, there was
no worsening of global PSQI scores (see Figure 4). On the
other hand, that the subjects reporting TEAEs unrelated to
sleep showed a slight improvement in PSQI scores, raises
the possibility that in the absence of TEAEs that affect
sleep, PSQI-measured sleep quality may improve with
treatment. Since sleep-related TEAEs did occur in some
subjects while overall sleep quality by group did not
worsen, the possibility also exists that improvement in the
PSQI global scores for subjects reporting sleep-related TEAEs Figure 4
PSQI global scores for subjects reporting sleep-related TEAEs. PSQI scores are not worse at 4 weeks for subjects 
who reported sleep-related TEAEs. Numbers within bars indicate numbers of subjects. (TEAEs = treatment-emergent adverse 
events; PSQI = Pittsburgh Sleep Quality Index; LDX = lisdexamfetamine dimesylate; SD = standard deviation).
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Table 5: Incidence of TEAEs Associated With Discontinuation
Placebo
(n = 62)
30 mg/d LDX
(n = 119)
50 mg/d LDX
(n = 117)
70 mg/d LDX
(n = 122)
Active Doses
(n = 358)
Discontinuation, n (%)
Insomnia 0 (0) 2 (1.7) 3 (2.6) 3 (2.5) 8 (2.2)
Sleep disorder 0 (0) 0 (0) 1 (0.9) 0 (0) 1 (0.3)
Hypersomnia 0 (0) 1 (0.8) 0 (0) 0 (0) 1 (0.3)Behavioral and Brain Functions 2009, 5:34 http://www.behavioralandbrainfunctions.com/content/5/1/34
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daytime functioning component of the global PSQI rating
may have masked deterioration in other components of
sleep quality for some individuals. When considering the
significance of such correlations, however, it is important
to keep in mind that AEs were collected as spontaneous
reports weekly and measured discrete, new events with an
onset in the preceding week, while the PSQI is designed to
assess sleep quality during the month preceding assess-
ment [51].
This study has several limitations. Adults with comorbid
psychiatric disease were excluded from the current study,
potentially limiting generalization of these results to the
broader adult population with ADHD. Additionally, sub-
jects with severe pre-existing insomnia may not have cho-
sen to participate in this study due to the potential for
stimulants to affect sleep. This study was designed as a pla-
cebo-controlled, forced dose-titration trial, and, therefore,
no active comparator was employed and subjects may not
have been receiving a dose of LDX that provided optimal
balance between efficacy and tolerability. The current
study assessed sleep parameters using the PSQI, a self-
report measure that is potentially affected by subject-spe-
cific inaccuracies in reporting sleep characteristics. Further
research with sleep parameters as a primary objective and
using optimized dose design and polysomnography or
actigraphy, which would allow for more objective sleep
measurements, would be useful in further characterizing
the potential for detrimental effects of long-acting stimu-
lants on sleep. Despite these limitations, this study pro-
vides further evidence that LDX demonstrated a safety
profile similar to other stimulant medications for the
treatment of adults with ADHD with no overall worsening
of sleep quality.
Conclusion
In this population of adults with ADHD, sleep quality at
baseline, as assessed by the PSQI, was generally poor. In
those subjects who reported sleep-related TEAEs, PSQI
scores were no different from placebo. These findings
highlight the importance of relying on data beyond the
frequency count of insomnia and other sleep-related AEs
in determining the potential clinical relevance of adverse
effects of stimulants on sleep parameters. LDX was found
to significantly improve self-reported daytime functioning
and, despite reports of insomnia as a TEAE, treatment
with LDX was not associated with an overall worsening of
self-reported sleep quality, sleep onset latency, sleep dura-
tion, or sleep disturbances. Sleep-related TEAEs associated
with LDX treatment were generally mild or moderate in
severity, led to few discontinuations, and decreased inci-
dence after the first week of treatment. These results sug-
gest that the global sleep quality of subjects on LDX and
placebo is no different and that daytime functioning in
adults with ADHD on LDX significantly improves. To
improve compliance, treatment of adults with ADHD in
clinical practice may be enhanced by closer monitoring of
patients for sleep-related AEs. Perhaps including an assess-
ment tool such as the PSQI, which complements sponta-
neously reported sleep-related AEs in clinical practice,
may also contribute to improved outcomes and compli-
ance.
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